2019 International Congress » Drug-Induced Movement Disorders

1:45pm-3:15pm

A case of donepezil-induced multifocal myoclonus

C. Amlang, P. Kim, A. Padalia, B. Roy, S. Schaefer (New Haven, CT, USA)

1:45pm-3:15pm

A Case of Pregabalin induced Parkinsonism

BC. Ari, F. Mayda Domac, G. Ozgen Kenangil (Istanbul, Turkey)

1:45pm-3:15pm

An unusual cause of rhabdomyolysis in the patients with Parkinson’s disease: A report of two cases

J. Srikajon, P. Srivanitchapoom, Y. Pitakpatapee, T. Sangpeamsook, C. Satukijchai, A. Suengtaworn (Bangkok, Thailand)

1:45pm-3:15pm

Brain neurotransmitters and neuropeptides alternations in Parkinson’s induced mouse models

N. Kumar, R. Khanna (Jaipur, India)

1:45pm-3:15pm

Chlorogenic acid and Trianthema portulacastrum combinational therapy mitigates rotenone induced Parkinsonism in wistar rats

E. Yadav (Prayagraj, India)

1:45pm-3:15pm

Clinically Relevant Changes in AIMS Based on Clinical and Patient Global Impression of Change in Patients With Tardive Dyskinesia Treated with Deutetrabenazine

H. Barkay, A. Wilhelm, M. Wieman, M. Gordon, R. Hauser, JM. Savola (Netanya, Israel)

1:45pm-3:15pm

Clonazepam as a cure or a cause? : Withdrawal Emergent Syndrome

S. Raju, K. Vyas (Bangalore, India)

1:45pm-3:15pm

Combination Antiretroviral therapy (cART)-induced cerebellar and prefrontal cortex disorders: A Study on the impact of Naringenin and Quercetin

E. Akang, O. Dosumu, A. Fagaroye, I. Usman, A. Oremosu, A. Akanmu (Lagos, Nigeria)

1:45pm-3:15pm

Drug-induced Negative Myoclonus: A Case Report

L. Lerjefors, M. Mainardi, A. Antonini, M. Carecchio (Padova, Italy)

1:45pm-3:15pm

Drug-Induced Parkinsonism May Persist Beyond Two Years After Discontinuation of Dopamine Transmission Blocking Agents

J. Randhawa, R. Mehanna (Houston, TX, USA)

1:45pm-3:15pm

High dose amantadine therapy may cause increased falling in Parkinson’s patients

L. Verhagen Metman (Chicago, IL, USA)

1:45pm-3:15pm

Long-Term Outcomes in Patients with Tardive Dyskinesia who Were Early Responders with Valbenazine

S. Factor, C. Comella, S. Marder, J. Burke, K. Farahmand, S. Siegert (Atlanta, GA, USA)

1:45pm-3:15pm

Long-Term Outcomes with Valbenazine 40 mg/day in Adults with Tardive Dyskinesia

S. Marder, C. Comella, C. Singer, C. Chepke, J. Burke, K. Farahmand, S. Siegert (Los Angeles, CA, USA)

1:45pm-3:15pm

Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia: Results From an Open-Label Extension Study

R. Hauser, H. Barkay, H. Fernandez, S. Factor, J. Jimenez-Shahed, N. Gross, M. Gordon, JM. Savola, K. Anderson (Tampa, FL, USA)

1:45pm-3:15pm

Memantine induced dyskinesia in Alzheimer’s disease

M. Kaiserova, L. Hvizdošova, K. Mensikova, P. Kanovsky (Olomouc, Czech Republic)

1:45pm-3:15pm

Moving ear syndrome secondary to bromopride and response to botulinum toxin

F. Sekeff-Sallem, J. Pedroso, O. Barsottini (Sao Paulo, Brazil)

1:45pm-3:15pm

Neurological complications secondary to metronidazole: Case Report

M. Teran, P. Salles (Santiago, Chile)

1:45pm-3:15pm

Patient-centered approach to elicit and compare the treatment goals of patients with tardive dyskinesia, their care partners, and healthcare providers

C. Kutz (Colorado Springs, CO, USA)

1:45pm-3:15pm

Protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease

S. Rajput, S. Sinha (New Delhi, India)

1:45pm-3:15pm

Quercetin administration abrogates the Parkinson’s disease (PD)-like motor and non-motor symptoms and attenuates the behavioral, neurochemical and biochemical deficits induced by rotenone toxicity in rats

S. Madiha, S. Haider (Karachi, Pakistan)

1:45pm-3:15pm

Re-emerging Neuroleptic Malignant Syndrome (NMS) without Re-introduced Neuroleptic in a Schizophrenia Patient: a Case Report

D. Tunjungsari, A. Tiksnadi (Jakarta, Indonesia)

1:45pm-3:15pm

Regardless of impaired renal function, negative myoclonus can be induced by gabapetin and pregabalin

DY. Kwon, MH. Park (Gyenggi-Do, Republic of Korea)

1:45pm-3:15pm

Smartphone-based gait assessment of psychiatric patients on neuroleptics

S. Hassin-Baer, T. Fay-Karmon, V. Livneh, S. Israeli-Korn, Y. Rubel, K. Tchelet, Z. Yekutieli, M. Linder, H. Yahalom, G. Yahalom (Ramat-Gan, Israel)

1:45pm-3:15pm

Steroid-responsive myoclonus in the context of pembrolizumab treatment: a novel neurological phenotype.

M. Murphy, S. O'Dowd, M. Alexander (Dublin, Ireland)

1:45pm-3:15pm

The dopamine receptor antagonist haloperidol enhances beta and gamma oscillations and bursts in the motor cortex

M. Alam, T. Doll, J. Krauss, K. Schwabe (Hannover, Germany)

1:45pm-3:15pm

Toning down SPNs to improve motor responses to dopaminergic stimulation in Parkinson’s disease

G. Beck, H. Mochizuki, S. Papa (Atlanta, GA, USA)

1:45pm-3:15pm

Waiting and waiting on Dopamine transporter imaging in drug induced parkinsonism

JY. Yun, CY. Lee, MY. Chun, B. Jeon (Seoul, Republic of Korea)